Aurobindo Pharma Unit-VII Receives US FDA Voluntary Action Indicated Classification
Aurobindo Pharma Limited's Unit-VII oral solid dosage manufacturing facility in Telangana has received a Voluntary Action Indicated (VAI) classification from the US FDA, following an inspection conducted from January 28 to February 10, 2026, which issued 9 Form 483 observations. The FDA has formally closed the inspection, and the development was disclosed under SEBI Regulation 30 by Company Secretary B. Adi Reddy on May 6, 2026.
*this image is generated using AI for illustrative purposes only.
Aurobindo Pharma Limited disclosed, pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, that its Unit-VII manufacturing facility has received a Voluntary Action Indicated (VAI) classification from the United States Food and Drug Administration (US FDA). The company communicated this development to both the National Stock Exchange of India Limited and BSE Limited through a formal regulatory filing signed by Company Secretary B. Adi Reddy.
US FDA Inspection Overview
The US FDA conducted an inspection of Aurobindo Pharma's Unit-VII, an oral solid dosage manufacturing unit, situated at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, 509302, Telangana. The key details of the inspection are summarised below:
| Parameter: | Details |
|---|---|
| Facility: | Unit-VII, Oral Solid Dosage Manufacturing Unit |
| Location: | SEZ (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, Telangana – 509302 |
| Inspection Period: | January 28 to February 10, 2026 |
| Form 483 Observations: | 9 |
| EIR Classification: | Voluntary Action Indicated (VAI) |
| Inspection Status: | Closed |
VAI Classification and Inspection Closure
Following the inspection, the US FDA issued a Form 483 with a total of 9 observations. Subsequently, the unit received the Establishment Inspection Report (EIR) classifying the facility as Voluntary Action Indicated (VAI). The FDA has formally concluded that the inspection is now closed. This disclosure was made in reference to the company's earlier communication dated February 10, 2026, which had informed the exchanges of the inspection and the issuance of Form 483.
Regulatory Disclosure
The filing was made in compliance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The disclosure was digitally signed by B. Adi Reddy, Company Secretary of Aurobindo Pharma Limited, on May 6, 2026. The company is headquartered at Galaxy, Floors 22-24, Plot No. 1, Survey No. 83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Historical Stock Returns for Aurobindo Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.36% | +5.86% | +10.32% | +29.64% | +22.20% | +46.54% |
How might the VAI classification for Unit-VII impact Aurobindo Pharma's pending ANDA approvals and new product launches targeting the US market from this facility?
Given that 9 Form 483 observations were issued before the VAI classification, what corrective action investments might Aurobindo need to sustain compliance and avoid future Warning Letters at this facility?
How does this VAI outcome for Unit-VII compare to the regulatory status of Aurobindo's other US FDA-regulated manufacturing facilities, and what does it signal about the company's overall compliance trajectory?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
